DHEA Peptide

Dehydroepiandrosterone (DHEA) is a C19 steroid hormone, not a peptide, synthesized primarily in the zona reticularis of the adrenal cortex with minor contributions from the gonads and brain. It is catalogued here under the hormone category as the body's most abundant circulating steroid precursor. In the liver, DHEA is rapidly sulfated to DHEAS, yielding a more stable conjugate with a half-life of approximately 13.7 hours compared with 1–3 hours for unconjugated DHEA.

In peripheral tissues, DHEA and DHEAS are converted intracrinally by tissue-specific steroidogenic enzymes into androgens (androstenedione, testosterone, dihydrotestosterone) and estrogens (estradiol, estrone). This intracrine mechanism allows localized sex hormone activity without proportionally elevating systemic circulating levels, enabling tissues such as vaginal epithelium, brain, adipose, and liver to regulate their own steroid environment.

Beyond its precursor role, DHEA and DHEAS exert direct receptor-mediated neuroactive effects. Both act as non-competitive GABA-A receptor antagonists, with DHEAS showing greater inhibitory potency. DHEAS potentiates NMDA receptor function to support synaptic plasticity, and acts as a sigma-1 receptor agonist activating neuroprotective downstream pathways. DHEA additionally signals through G protein-coupled receptors, activating MAPK and PI3K cascades that influence cell survival and anti-apoptotic signaling.

• Circulating DHEA/DHEAS peak between ages 20–30 and fall to roughly 20% of peak values by age 70, a process termed adrenopause • After menopause, DHEA becomes the dominant precursor for residual peripheral estrogen and androgen synthesis in women

The most robust human evidence for DHEA concerns its FDA-approved intravaginal form, prasterone (Intrarosa), indicated for moderate-to-severe dyspareunia associated with genitourinary syndrome of menopause (GSM). Regulatory approval in November 2016 was based on two 12-week, randomized, double-blind, placebo-controlled trials enrolling 640 postmenopausal women, which demonstrated statistically significant reductions in painful intercourse. Local vaginal tissue contains all steroidogenic enzymes necessary for DHEA conversion, achieving therapeutic benefit without substantially raising systemic sex hormone levels.

In reproductive medicine, a 2014 RCT (n=95; 42 receiving 75 mg/day oral DHEA for three menstrual cycles before IVF) found significantly higher follicular fluid BMP-15 concentrations (0.81 vs. 0.35 ng/mL, p<0.001), increased serum AMH, and higher accumulated embryo scores (4.24 vs. 2.87, p=0.033) in the treatment group. Oocyte retrieval numbers and pregnancy rates did not differ significantly between groups.

The DAWN trial (double-blind RCT, n=225 healthy adults aged 55–85, 50 mg/day oral DHEA for one year) found no statistically significant benefit over placebo on any measure of cognitive function, mood, quality of life, or sexual function despite raising serum DHEA 2–4-fold above baseline.

A 2021 meta-analysis of 21 RCT arms (n=1,223) found DHEA supplementation significantly elevated circulating estradiol by 7.02 pg/mL (95% CI: 5.43–8.62), with the largest effects in postmenopausal women over 60 taking 50 mg/day for at least 26 weeks.

Evidence for oral DHEA in anti-aging, bone mineral density, metabolic health, and autoimmune conditions is inconsistent across human trials. A 2022 review concluded that few controlled data support DHEA administration for sexual function, cognitive improvement, or general wellbeing in otherwise healthy women, and that large-scale RCTs are still needed.

Typical dosage: 25-50 mg (daily).

The only FDA-approved dosage form is prasterone (Intrarosa) as a 6.5 mg vaginal insert administered once daily at bedtime for genitourinary syndrome of menopause. The prescribing label carries no boxed warning and specifies no upper limit on treatment duration.

For oral supplementation, the following protocols appear in published literature and clinical practice:

• Anti-aging and hormone optimization: 5–50 mg/day orally, typically guided by baseline serum DHEAS measurement; many clinicians target restoration to the mid-normal range for sex and age • DAWN trial (general wellness in older adults): 50 mg/day orally for 12 months • IVF pretreatment in diminished ovarian reserve: 75 mg/day (25 mg three times daily) for 8–16 weeks before oocyte retrieval • Women generally: lower dosing (10–25 mg/day) is commonly recommended given greater sensitivity to androgenic conversion • Men in hormone optimization settings: 25–50 mg/day, sometimes alongside monitored testosterone therapy (anecdotal/clinical practice basis; no RCT support for this combination)

DHEA is sold over-the-counter as a dietary supplement in the United States but is a prescription-only substance in Canada, the United Kingdom, and most of Europe. It is classified as a prohibited substance by the World Anti-Doping Agency (WADA). Serum DHEAS monitoring before and periodically during supplementation is widely recommended to avoid supraphysiological exposure.

This information is provided for educational and reference purposes only and does not constitute medical advice. Dosing decisions should be made in consultation with a qualified healthcare provider based on individual hormone levels, health status, and clinical context.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The most commonly reported community and clinical practice combination is oral DHEA alongside testosterone replacement therapy (TRT) in men. The proposed rationale is that exogenous testosterone suppresses endogenous adrenal DHEA production, and supplementation is thought to preserve a broader adrenal hormone milieu. No published RCTs have evaluated this co-administration strategy, and the evidence base is anecdotal.

In reproductive medicine, DHEA pretreatment alongside gonadotropin stimulation protocols in women with diminished ovarian reserve before IVF represents the strongest evidence-supported combination context, backed by multiple small RCTs.

One small controlled trial suggested DHEA combined with supervised heavy resistance exercise produced greater gains in muscle mass and strength in elderly subjects than exercise alone. This is a preliminary, unreplicated finding.

In postmenopausal hormone replacement, DHEA is sometimes used in combination with or in place of systemic estrogen, leveraging its peripheral conversion to both androgens and estrogens. Most multi-agent hormone combinations incorporating DHEA outside the IVF setting are supported only by expert clinical opinion or observational data and should be regarded as anecdotal.

DHEA Peptide is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Possible acne, hormone fluctuations

The most consistently reported adverse effects of oral DHEA are androgenic: acne, oily skin, hirsutism, scalp itching, and hair thinning. These are dose-dependent and more frequent in women. In one clinical trial using only 25 mg/day, androgenic complaints including hirsutism and altered sweat odor were still documented in female participants. Sustained elevations in circulating estradiol and testosterone, sometimes exceeding normal premenopausal ranges, have been measured in women taking oral DHEA over six months.

For the intravaginal formulation, the most common adverse events in clinical trials were vaginal discharge and changes on Pap smear.

DHEA is contraindicated in individuals with known or suspected hormone-sensitive malignancies, including breast, ovarian, uterine, and prostate cancers, as downstream estrogen and androgen metabolites may promote tumor growth. Undiagnosed abnormal vaginal bleeding is a specific contraindication for the intravaginal form. DHEA may exacerbate estrogen-dependent conditions including endometriosis and uterine fibroids.

Drug interactions include potentiation of anticoagulants such as warfarin, possible interference with insulin sensitivity and diabetes medications, and potential interaction with aromatase inhibitors.

At doses up to 50 mg/day, oral DHEA has been used in published trials lasting up to two years without serious adverse events in healthy adults. Long-term safety at higher doses is inadequately characterized. Quality control of over-the-counter formulations is variable, with independent testing identifying significant content deviations in some products. Use is not recommended during pregnancy or lactation.